Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P0RX
|
|||
| Former ID |
DNCL002961
|
|||
| Drug Name |
Nemonoxacin
|
|||
| Synonyms |
Nemonoxacin; 378746-64-6; UNII-P94L0PVO94; TG-873870; P94L0PVO94; Nemonoxacin [INN]; 7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-[(3S,5S)-3-Amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; SCHEMBL1006373; CHEMBL1213456; CHEBI:136053; ZINC40435195; SB16570; FT-0700967; 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Community-acquired pneumonia [ICD-11: CA40.Z] | Approved | [1] | |
| infection associated with diabetic foot ulcers [ICD-11: BD54] | Phase 3 | [2] | ||
| Company |
TaiGen Biotechnology
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H25N3O4
|
|||
| Canonical SMILES |
CC1CC(CN(C1)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)OC)N
|
|||
| InChI |
1S/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1
|
|||
| InChIKey |
AVPQPGFLVZTJOR-RYUDHWBXSA-N
|
|||
| CAS Number |
CAS 378746-64-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:136053
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial DNA gyrase (Bact gyrase) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Nemonoxacin: first global approval. Drugs. 2014 Aug;74(12):1445-53. | |||
| REF 2 | TaiGen Biotechnology Announces Submission of New Drug Application for Nemonoxacin in Taiwan and Mainland China. TaiGen Biotechnology Co., Ltd. May 16, 2013. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.